|
|
Post by joeypotsandpans on May 12, 2015 19:49:59 GMT -5
CNBC put out their 50 disruptors for 2015 ( www.cnbc.com/id/102609977 ), of course MNKD cannot be on there as these are private companies so it's not mind boggling that they are not on the list but the company that is ranked 29th Intarcia Therapeutics is as they just raised a 225 million private placement for their implantable "matchstick" pump. It went through its first two of four phase III trials and it showed after 39 weeks that it dropped A1c 's vs. placebo from 10's to 7's with its GLP-1 (Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. www.prnewswire.com/news-releases/intarcia-announces-two-positive-phase-3-trials-for-itca-650-in-type-2-diabetes-freedom-1-and-freedom-1-high-baseline-hbl-study-results-277838961.html ) So here is why its mind boggling...when interviewed they talked about how they expect a 5.5 billion valuation in the not too distant future (they are hopeful to have it in the market some time in 2017 btw, perhaps someone should tell them by no means should they make any changes to the design.) While here we sit with an insulin that is showing to take A1c's to unprecedented levels in the early adopters ie., Sam,Brian, & now Jackie (can't leave out Spiro too) within 90 days. Ironically, their private placement came just a couple of days before the SNY and MNKD conf. calls, but it wouldn't surprise me who the brokerage houses are that are looking to do their IPO and tout them up to that 5.5 billion valuation. It looks like they are going to target the type II's who would still have to take orals in conjunction with the implanted pumps, at least that's the way I read it. Either way, it looks like our little disruptor is not only stepping on the toes of current BP but the upstarts as well  Btw, JPG it looks like your estimate of 2017 was closer to the mark: mnkd.proboards.com/post/10647 |
|
|
|
Post by centralcoastinvestor on May 12, 2015 22:11:02 GMT -5
I was thinking about Mnkd and Afrezza when I saw the CNBC Disruptor 50. I thought about the huge paradigm change that Afrezza is now causing and got frustrated at how CNBC seems to ignore Afrezza and Al Mann. I truly believe that in the not so distant future, Afrezza will lead many national news stories.
|
|
|
|
Post by sportsrancho on May 13, 2015 7:02:41 GMT -5
Was thinking the same thing when I watched the video of Afrezza on that small news channel. Soon we will be the talk of the town. But right now we are right under their nose and they don't even know it! This is going to be very exciting:-))).
|
|
|
|
Post by mnholdem on May 13, 2015 9:37:28 GMT -5
Agreed. I'm not sure that even Sanofi has unraveled all the medical benefits to Afrezza. Of course, Al Mann has known of these health benefits (ie lowering insulin intolerance or regenerating pancreatic beta cells) for years and has tried to get the press excited.
It's all one big money game to CNBC.
|
|
|
|
Post by joeypotsandpans on Oct 27, 2015 17:10:50 GMT -5
CNBC put out their 50 disruptors for 2015 ( www.cnbc.com/id/102609977 ), of course MNKD cannot be on there as these are private companies so it's not mind boggling that they are not on the list but the company that is ranked 29th Intarcia Therapeutics is as they just raised a 225 million private placement for their implantable "matchstick" pump. It went through its first two of four phase III trials and it showed after 39 weeks that it dropped A1c 's vs. placebo from 10's to 7's with its GLP-1 (Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. www.prnewswire.com/news-releases/intarcia-announces-two-positive-phase-3-trials-for-itca-650-in-type-2-diabetes-freedom-1-and-freedom-1-high-baseline-hbl-study-results-277838961.html ) So here is why its mind boggling...when interviewed they talked about how they expect a 5.5 billion valuation in the not too distant future (they are hopeful to have it in the market some time in 2017 btw, perhaps someone should tell them by no means should they make any changes to the design.) While here we sit with an insulin that is showing to take A1c's to unprecedented levels in the early adopters ie., Sam,Brian, & now Jackie (can't leave out Spiro too) within 90 days. Ironically, their private placement came just a couple of days before the SNY and MNKD conf. calls, but it wouldn't surprise me who the brokerage houses are that are looking to do their IPO and tout them up to that 5.5 billion valuation. It looks like they are going to target the type II's who would still have to take orals in conjunction with the implanted pumps, at least that's the way I read it. Either way, it looks like our little disruptor is not only stepping on the toes of current BP but the upstarts as well Btw, JPG it looks like your estimate of 2017 was closer to the mark: mnkd.proboards.com/post/10647Apologize in advance if this has been brought up since I saw it last Friday but after glancing through the board which I have not had much time to do lately I didn't see it mentioned. Last Friday Cramer had on his show I believe the CEO of Intarcia and actually had him show the audience the implantation of the device and review the "benefits" it will have as a "disruptive" technology for specifically T2 diabetics. One thing that stood out to me was the CEO stated that currently the only options available for T2's was injection and oral meds taken daily....no mention whatsoever of inhalable (obviously considered another disruptive technology). They went on to talk about how it would be a viable competitor to existing BP's with respect to treating Diabetes and potentially other chronic diseases through its implantable pump. It still makes one chuckle to see him endorse a privately held company that has yet to come to market versus his skeptical attitude and projected cynicism directed toward MNKD whenever asked. So it wouldn't surprise me to see this as the beginning of the "dog and pony" show leading up to a soon to be IPO IMO. Oh yeah btw, exenatide which is currently being used as Byetta and Bydureon has an interesting history regarding its side effects, labeling, etc. with various concerns and statements from the FDA in the past... www.byettahcp.com/dosing-and-administration ....looks to me like nothing still compares to plain old human insulin but just found it interesting how much Cramer/CNBC have mentioned this "up and coming" disruptor ...pass me the tin foil hat please |
|
|
|
Post by dreamboatcruise on Oct 27, 2015 18:22:08 GMT -5
Not to mention. Who wants a matchstick shoved under their skin when they could inhale their GLP-1?
|
|
|
|
Post by mnholdem on Oct 27, 2015 19:19:03 GMT -5
If I'm not mistaken, one of Al Mann's other companies here in Minnesota has a similar implantable infusion pump in Phase 2/3 trials. Clinical Trial NTC01185470. If you're really a glutton, check out the numerous patents of Medallion Therapeutics, including a programming device for their implantable pump that includes a display device, a communication device and a controller.
It's a very cool company whose CEO came from Medtronic.
As far as Cramer goes, somebody should remind him that Mann already has two "disruptors" to his name. The first was his company's invention of a long-lasting battery that made the pacemaker possible. His second disruptive invention was, of course, the Minimed insulin pump. Technosphere is Mann's third and possibly will become his greatest disruptor, one that - like a stem cell - may spawn many, many disruptive drugs.
|
|
